CAMBISeq

222,000.00

Get the test that is the most effective way of monitoring your cancer patient’s status, during and after treatment. Get CAMBISeq. CAMBISeq allows you to forecast your patient’s response to immunotherapy and to detect variants.

Principal

Research Genetics Cancer Centre, RGCC (Florina, Greece)

Description

(Cancer Analysis, Mutational Burden and Instability sequencing) helps identify variants in more than 500 genes, detect fusions and calculate tumour mutational burden (TMB) and microsatellite instability (MSI)

Indications

Cancer

Specimen

10 – 20 ml blood or tissue specimen

Preparation

No preparation needed

Methodology

Next Generation Sequencing

MONITOR YOUR CONDITION AS CLOSELY AS POSSIBLE DURING CANCER TREATMENT AND AFTER

CAMBISeq identifies variants in more than 500 genes, detects fusions, and calculates tumor mutational burden (TMB) and microsatellite instability (MSI). These mutations, within the coding region, are used as biomarkers of sensitivity to immunotherapy.

The test is for all kinds of cancer.

Medical Practitioner showing the patient recovery results after cancer treatment
Explainer video coming soon

HOW CAMBISEQ CAN HELP YOUR PATIENTS

  • A more accurate and comprehensive way of monitoring your status during and after cancer treatment
  • Can be a way of knowing if treatments were effective and what future treatments can be prescribed
  • Allows for comprehensive genomic profiling
  • Achieves reliable results with the test having 99.99 percent specificity and more than 95 percent sensitivity
  • Studying cells isolated from a blood sample or tissue sample, CAMBISeq incorporates biomarkers covering different types of cancer (lung, melanoma, colon, breast, sarcoma, myeloid, etc). This requires lower input, detects low-frequency mutations and is cost-effective.

OTHER HELPFUL INFORMATION FOR YOUR PATIENTS

  • There is no need for the patient to follow a special diet before the blood sample is taken.
  • If the patient is having chemotherapy treatment, the sample must be taken at least seven days after the last chemotherapy.
  • Blood samples require 7-10 ml of venous blood.
  • Turnaround time: 2-4 weeks

END-TO-END PROCEDURE

  1. The doctor will prescribe the test.
  2. GMT’s key account manager will get in touch with you to schedule the extraction of the sample. They will also answer additional questions you might have with the procedure.
  3. GMT’s medical technologist will personally go to the agreed location to collect the sample.
  4. The specimen will then be analyzed in the laboratory.

USE GENOMIC PROFILING TO KNOW YOUR PATIENT’S RESPONSE TO TREATMENT

CAMBISeq (cancer analysis, mutational burden, and instability sequencing) is able to perform next-generation sequencing analysis on both DNA and RNA to predict a patient’s response to immunotherapy and to detect variants.

The test identifies variants in more than 500 genes, detects fusions, and calculates tumors, mutational burden (TMB), and microsatellite instability (MSI). These identified mutations within the coding region are then used as biomarkers of sensitivity to immunotherapy.

Feel Free to Reach Us. Let’s Talk!

Not yet Decided? Leave your contact info with us. So we can chat about your health.

Name *
Fill out this field
Email *
Please enter a valid email address.
Contact Number *
Fill out this field
Message
Fill out this field

Follow Our Social Media

YOUR PATIENTS MIGHT ALSO NEED TO TAKE

Menu